RxDoctor Payments DataLook up a doctor →

Susan Sharifi, MD

Neurology · Terre Haute, INNPI 1790896769

Payments from drug & device makers

$139,583in general payments, 2019–2025

Across 1,168 payments — averaging $119.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$34K
  • Amgen$28K
  • AbbVie$19K
  • Lilly USA, LLC$18K
  • Biohaven Pharmaceutical Holding Company Ltd.$12K
  • Biohaven Pharmaceuticals, Inc.$5K
  • plus $23K from 54 others

What the payments were for

  • Consulting fees$3,5753%
  • Speaking & faculty fees$105,96976%
  • Travel & lodging$6,0344%
  • Food & beverage$22,85016%
  • Education$1,1541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.91$34,095
Amgen56$28,265
AbbVie(2 entities)148$18,693
Lilly USA, LLC60$18,212
Biohaven Pharmaceutical Holding Company Ltd.15$11,880
Biohaven Pharmaceuticals, Inc.16$5,144
Livanova USA, Inc.19$3,126
Promius Pharma LLC9$3,045
EMD Serono, Inc.69$1,971
Pfizer18$1,923
Novartis66$1,185
MDD US Operations, LLC35$887
Sanofi31$862
UCB, Inc.42$779
AstraZeneca(2 entities)27$698
Eisai Inc.28$690
Jazz Pharmaceuticals Inc.13$613
SK Life Science, Inc.22$572
Supernus Pharmaceuticals, Inc.111$549
Lundbeck LLC21$484
TG Therapeutics, Inc.9$392
Harmony Biosciences LLC9$334
Argenx US, Inc.14$315
Axsome Therapeutics, Inc.8$301
Idorsia Pharmaceuticals US Inc6$282
Neurocrine Biosciences, Inc.14$250
Arbor Pharmaceuticals, Inc.14$224
Greenwich Biosciences, Inc.7$224
Neurelis, Inc.5$215
Biogen14$211
Genentech USA, Inc.13$203
Acadia Pharmaceuticals Inc12$170
Sunovion Pharmaceuticals Inc.18$168
Amneal Pharmaceuticals LLC10$167
Adamas Pharmaceuticals, Inc.9$149
Upsher-smith Laboratories LLC8$146
E.r. Squibb & Sons, L.L.C.2$145
Catalyst Pharmaceuticals, Inc.2$143
CSL Behring7$137
Avanir Pharmaceuticals, Inc.8$128
Otsuka America Pharmaceutical, Inc.5$117
Assertio Therapeutics, Inc.8$116
Grifols USA, LLC6$98
Tonix Medicines, Inc.3$96
Ipsen Biopharmaceuticals, Inc4$93
Johnson & Johnson4$87
Tanabe Pharma America, Inc.4$78
Sumitomo Pharma America, Inc.8$76
Kyowa Kirin, Inc.3$72
Banner Life Sciences, LLC3$72
Acorda Therapeutics, Inc3$64
Bristol Myers Squibb3$63
Almatica Pharma LLC4$54
Saol Therapeutics Inc.3$54
Mallinckrodt Hospital Products Inc.2$53
Corium, LLC2$51
Azurity Pharmaceuticals, Inc.2$48
Boston Scientific2$41
GE HealthCare1$36
Cycle Pharmaceuticals Inc1$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$139,583 in reported general payments places this provider in the 85th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$186,250
Medicare patients
371
Services billed
14,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate271$410,118
QuliptaAtogepant204$322,205
UbrelvyUbrogepant146$237,715
IngrezzaValbenazine Tosylate24$197,273
Austedo XrDeutetrabenazine24$175,594
AubagioTeriflunomide12$112,837
AptiomEslicarbazepine Acetate33$112,536
XcopriCenobamate50$75,764
BriviactBrivaracetam42$75,444
Topiramate ErTopiramate61$58,683
Ajovy AutoinjectorFremanezumab-Vfrm43$53,441
Emgality PenGalcanezumab-Gnlm40$44,488
ZavzpretZavegepant Hcl31$39,492
Aimovig AutoinjectorErenumab-Aooe37$36,898
FycompaPerampanel13$33,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Savella$18,693$574,600367 claims
PfizerNurtec Odt, Zavzpret, Dilantin$1,923$452,119315 claims
Neurocrine Biosciences, Inc.Ingrezza$250$197,27324 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$34,095$175,59424 claims
SanofiAubagio$862$112,83712 claims
Sunovion Pharmaceuticals Inc.Aptiom$168$112,53633 claims
SK Life Science, Inc.Xcopri$572$75,76450 claims
UCB, Inc.Briviact$779$75,44442 claims
Eisai Inc.Fycompa$690$33,51313 claims
Avanir Pharmaceuticals, Inc.Nuedexta$128$31,02529 claims
Upsher-smith Laboratories LLCTopiramate$146$3,187282 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 neurology providers in Indiana.

Other neurology in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →